Comparison of IFN-β inducible gene expression in primary-progressive and relapsing-remitting multiple sclerosis

Journal of Neuroimmunology

Volumn 265, Issue 1-2, 2013, Pages 68-74

  Boppana, Sridhar ^a   Mindur, John E ^a   Balashov, Konstantin E ^a   Dhib Jalbut, Suhayl ^a   Ito, Kouichi ^a,b  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b Department of Neurology ^*  (United States)

Author keywords

HLA G PPMS; IFN beta inducible genes; IFN beta therapy; Multiple sclerosis; PPMS; RRMS

Indexed keywords

BETA INTERFERON; HLA G ANTIGEN;

ARTICLE; CELL ISOLATION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG RESPONSE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE INDUCTION; GENETIC ASSOCIATION; HLA G GENE; HUMAN; HUMAN CELL; IFN BETA GENE; IMMUNE DYSREGULATION; IMMUNOMODULATION; IMMUNOREGULATION; IN VITRO STUDY; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

HLA-G PPMS; IFN BETA INDUCIBLE GENES; IFN BETA THERAPY; MULTIPLE SCLEROSIS; PPMS; RRMS;

HLA-G ANTIGENS; HUMANS; INTERFERON-BETA; INTERLEUKIN-1BETA; LEUKOCYTES, MONONUCLEAR; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; UP-REGULATION;

EID: 84888391352     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2013.10.007     Document Type: Article

References (65)

1. Androlewicz M.J., Ortmann B., van Endert P.M., Spies T., Cresswell P. Characteristics of peptide and major histocompatibility complex class I/beta 2-microglobulin binding to the transporters associated with antigen processing (TAP1 and TAP2). Proc. Natl. Acad. Sci. U. S. A. 1994, 91:12716-12720.
2. Bitsch A., Schuchardt J., Bunkowski S., Kuhlmann T., Bruck W. Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation. Brain 2000, 123(Pt 6):1174-1183.
3. Bjartmar C., Wujek J.R., Trapp B.D. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J. Neurol. Sci. 2003, 206:165-171.
4. Byrnes A.A., McArthur J.C., Karp C.L. Interferon-beta therapy for multiple sclerosis induces reciprocal changes in interleukin-12 and interleukin-10 production. Ann. Neurol. 2002, 51:165-174.
5. Chen Y.C., Chen S.D., Miao L., Liu Z.G., Li W., Zhao Z.X., Sun X.J., Jiang G.X., Cheng Q. Serum levels of interleukin (IL)-18, IL-23 and IL-17 in Chinese patients with multiple sclerosis. J. Neuroimmunol. 2012, 243:56-60.
6. Cockerill P.N., Osborne C.S., Bert A.G., Grotto R.J. Regulation of GM-CSF gene transcription by core-binding factor. Cell Growth Differ. 1996, 7:917-922.
7. Confavreux C., Vukusic S., Moreau T., Adeleine P. Relapses and progression of disability in multiple sclerosis. N. Engl. J. Med. 2000, 343:1430-1438.
8. Constam D.B., Tobler A.R., Rensing-Ehl A., Kemler I., Hersh L.B., Fontana A. Puromycin-sensitive aminopeptidase. Sequence analysis, expression, and functional characterization. J. Biol. Chem. 1995, 270:26931-26939.
9. DeLuca G.C., Williams K., Evangelou N., Ebers G.C., Esiri M.M. The contribution of demyelination to axonal loss in multiple sclerosis. Brain 2006, 129:1507-1516.
10. Dhib-Jalbut S., Marks S. Interferon-beta mechanisms of action in multiple sclerosis. Neurology 2010, 74(Suppl. 1):S17-S24.
11. Djuretic I.M., Levanon D., Negreanu V., Groner Y., Rao A., Ansel K.M. Transcription factors T-bet and Runx3 cooperate to activate Ifng and silence Il4 in T helper type 1 cells. Nat. Immunol. 2007, 8:145-153.
12. Ersoy E., Kus C.N., Sener U., Coker I., Zorlu Y. The effects of interferon-beta on interleukin-10 in multiple sclerosis patients. Eur. J. Neurol. 2005, 12:208-211.
13. Everett R.D., Rechter S., Papior P., Tavalai N., Stamminger T., Orr A. PML contributes to a cellular mechanism of repression of herpes simplex virus type 1 infection that is inactivated by ICP0. J. Virol. 2006, 80:7995-8005.
14. Favier B., LeMaoult J., Carosella E.D. Functions of HLA-G in the immune system. Tissue Antigens 2007, 69(Suppl. 1):150-152.
15. Ferguson B., Matyszak M.K., Esiri M.M., Perry V.H. Axonal damage in acute multiple sclerosis lesions. Brain 1997, 120(Pt 3):393-399.
16. Frischer J.M., Bramow S., Dal-Bianco A., Lucchinetti C.F., Rauschka H., Schmidbauer M., Laursen H., Sorensen P.S., Lassmann H. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009, 132:1175-1189.
17. Furlan R., Bergami A., Lang R., Brambilla E., Franciotta D., Martinelli V., Comi G., Panina P., Martino G. Interferon-beta treatment in multiple sclerosis patients decreases the number of circulating T cells producing interferon-gamma and interleukin-4. J. Neuroimmunol. 2000, 111:86-92.
18. Galbiati F., Volonte D., Liu J., Capozza F., Frank P.G., Zhu L., Pestell R.G., Lisanti M.P. Caveolin-1 expression negatively regulates cell cycle progression by inducing G(0)/G(1) arrest via a p53/p21(WAF1/Cip1)-dependent mechanism. Mol. Biol. Cell 2001, 12:2229-2244.
19. Garg S., Sharma M., Ung C., Tuli A., Barral D.C., Hava D.L., Veerapen N., Besra G.S., Hacohen N., Brenner M.B. Lysosomal trafficking, antigen presentation, and microbial killing are controlled by the Arf-like GTPase Arl8b. Immunity 2011, 35:182-193.
20. Graber J.J., Ford D., Zhan M., Francis G., Panitch H., Dhib-Jalbut S. Cytokine changes during interferon-beta therapy in multiple sclerosis: correlations with interferon dose and MRI response. J. Neuroimmunol. 2007, 185:168-174.
21. Hallal-Longo D.E., Mirandola S.R., Oliveira E.C., Farias A.S., Pereira F.G., Metze I.L., Brandao C.O., Ruocco H.H., Damasceno B.P., Santos L.M. Diminished myelin-specific T cell activation associated with increase in CTLA4 and Fas molecules in multiple sclerosis patients treated with IFN-beta. J. Interferon Cytokine Res. 2007, 27:865-873.
22. Hauser S.L., Oksenberg J.R. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 2006, 52:61-76.
23. Hesse D., Krakauer M., Lund H., Sondergaard H.B., Limborg S.J., Sorensen P.S., Sellebjerg F. Disease protection and interleukin-10 induction by endogenous interferon-beta in multiple sclerosis?. Eur. J. Neurol. 2011, 18:266-272.
24. Higgins J.J. An introduction to modern nonparametric statistics 2004, xviii. Thomson, Brooks/Cole, Pacific Grove, CA, (366 pp.).
25. Hundeshagen A., Hecker M., Paap B.K., Angerstein C., Kandulski O., Fatum C., Hartmann C., Koczan D., Thiesen H.J., Zettl U.K. Elevated type I interferon-like activity in a subset of multiple sclerosis patients: molecular basis and clinical relevance. J. Neuroinflammation 2012, 9:140.
26. Jørgensen P.B., Livbjerg A.H., Hansen H.J., Petersen T., Hollsberg P. Epstein-Barr virus peptide presented by HLA-E is predominantly recognized by CD8(bright) cells in multiple sclerosis patients. PLoS One 2012, 7:e46120.
27. Kitoh A., Ono M., Naoe Y., Ohkura N., Yamaguchi T., Yaguchi H., Kitabayashi I., Tsukada T., Nomura T., Miyachi Y., Taniuchi I., Sakaguchi S. Indispensable role of the Runx1-Cbfbeta transcription complex for in vivo-suppressive function of FoxP3+ regulatory T cells. Immunity 2009, 31:609-620.
28. Klunker S., Chong M.M., Mantel P.Y., Palomares O., Bassin C., Ziegler M., Ruckert B., Meiler F., Akdis M., Littman D.R., Akdis C.A. Transcription factors RUNX1 and RUNX3 in the induction and suppressive function of Foxp3+ inducible regulatory T cells. J. Exp. Med. 2009, 206:2701-2715.
29. Korporal M., Haas J., Balint B., Fritzsching B., Schwarz A., Moeller S., Fritz B., Suri-Payer E., Wildemann B. Interferon beta-induced restoration of regulatory T-cell function in multiple sclerosis is prompted by an increase in newly generated naive regulatory T cells. Arch. Neurol. 2008, 65:1434-1439.
30. Kozovska M.E., Hong J., Zang Y.C., Li S., Rivera V.M., Killian J.M., Zhang J.Z. Interferon beta induces T-helper 2 immune deviation in MS. Neurology 1999, 53:1692-1697.
31. Kulpa D.A., Collins K.L. The emerging role of HLA-C in HIV-1 infection. Immunology 2011, 134:116-122.
32. Kutzelnigg A., Lucchinetti C.F., Stadelmann C., Bruck W., Rauschka H., Bergmann M., Schmidbauer M., Parisi J.E., Lassmann H. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005, 128:2705-2712.
33. Leary S.M., Miller D.H., Stevenson V.L., Brex P.A., Chard D.T., Thompson A.J. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology 2003, 60:44-51.
34. Li C., Toth I., Schulze Zur Wiesch J., Pereyra F., Rychert J., Rosenberg E.S., van Lunzen J., Lichterfeld M., Yu X.G. Functional characterization of HLA-G(+) regulatory T cells in HIV-1 infection. PLoS Pathog. 2013, 9:e1003140.
35. Malhotra S., Bustamante M.F., Perez-Miralles F., Rio J., Ruiz de Villa M.C., Vegas E., Nonell L., Deisenhammer F., Fissolo N., Nurtdinov R.N., Montalban X., Comabella M. Search for specific biomarkers of IFNbeta bioactivity in patients with multiple sclerosis. PLoS One 2011, 6:e23634.
36. Martins T.B., Rose J.W., Jaskowski T.D., Wilson A.R., Husebye D., Seraj H.S., Hill H.R. Analysis of proinflammatory and anti-inflammatory cytokine serum concentrations in patients with multiple sclerosis by using a multiplexed immunoassay. Am. J. Clin. Pathol. 2011, 136:696-704.
37. Miller D.H., Leary S.M. Primary-progressive multiple sclerosis. Lancet Neurol. 2007, 6:903-912.
38. Mitsdoerffer M., Schreiner B., Kieseier B.C., Neuhaus O., Dichgans J., Hartung H.P., Weller M., Wiendl H. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis. J. Neuroimmunol. 2005, 159:155-164.
39. Montalban X., Sastre-Garriga J., Tintore M., Brieva L., Aymerich F.X., Rio J., Porcel J., Borras C., Nos C., Rovira A. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. Mult. Scler. 2009, 15:1195-1205.
40. Muirhead K.A., Wallace P.K., Schmitt T.C., Frescatore R.L., Franco J.A., Horan P.K. Methodological considerations for implementation of lymphocyte subset analysis in a clinical reference laboratory. Ann. N. Y. Acad. Sci. 1986, 468:113-127.
41. Naji A., Le Rond S., Durrbach A., Krawice-Radanne I., Creput C., Daouya M., Caumartin J., LeMaoult J., Carosella E.D., Rouas-Freiss N. CD3+CD4low and CD3+CD8low are induced by HLA-G: novel human peripheral blood suppressor T-cell subsets involved in transplant acceptance. Blood 2007, 110:3936-3948.
42. Namdar A., Nikbin B., Ghabaee M., Bayati A., Izad M. Effect of IFN-beta therapy on the frequency and function of CD4(+)CD25(+) regulatory T cells and Foxp3 gene expression in relapsing-remitting multiple sclerosis (RRMS): a preliminary study. J. Neuroimmunol. 2010, 218:120-124.
43. Pette M., Pette D.F., Muraro P.A., Farnon E., Martin R., McFarland H.F. Interferon-beta interferes with the proliferation but not with the cytokine secretion of myelin basic protein-specific, T-helper type 1 lymphocytes. Neurology 1997, 49:385-392.
44. Pietra G., Romagnani C., Mazzarino P., Falco M., Millo E., Moretta A., Moretta L., Mingari M.C. HLA-E-restricted recognition of cytomegalovirus-derived peptides by human CD8+ cytolytic T lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:10896-10901.
45. Ramgolam V.S., Sha Y., Jin J., Zhang X., Markovic-Plese S. IFN-beta inhibits human Th17 cell differentiation. J. Immunol. 2009, 183:5418-5427.
46. Rep M.H., Hintzen R.Q., Polman C.H., van Lier R.A. Recombinant interferon-beta blocks proliferation but enhances interleukin-10 secretion by activated human T-cells. J. Neuroimmunol. 1996, 67:111-118.
47. Rojas J.I., Romano M., Ciapponi A., Patrucco L., Cristiano E. Interferon Beta for primary progressive multiple sclerosis. Cochrane Database Syst Rev 2010, CD006643.
48. Rowell E.A., Walsh M.C., Wells A.D. Opposing roles for the cyclin-dependent kinase inhibitor p27kip1 in the control of CD4+ T cell proliferation and effector function. J. Immunol. 2005, 174:3359-3368.
49. Rudick R.A., Ransohoff R.M., Peppler R., VanderBrug Medendorp S., Lehmann P., Alam J. Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis. Ann. Neurol. 1996, 40:618-627.
50. Saresella M., Marventano I., Longhi R., Lissoni F., Trabattoni D., Mendozzi L., Caputo D., Clerici M. CD4+CD25+FoxP3+PD1- regulatory T cells in acute and stable relapsing-remitting multiple sclerosis and their modulation by therapy. FASEB J. 2008, 22:3500-3508.
51. Sellebjerg F., Krakauer M., Hesse D., Ryder L.P., Alsing I., Jensen P.E., Koch-Henriksen N., Svejgaard A., Soelberg Sorensen P. Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation. Eur. J. Neurol. 2009, 16:1291-1298.
52. Sturzebecher S., Wandinger K.P., Rosenwald A., Sathyamoorthy M., Tzou A., Mattar P., Frank J.A., Staudt L., Martin R., McFarland H.F. Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. Brain 2003, 126:1419-1429.
53. Towne C.F., York I.A., Neijssen J., Karow M.L., Murphy A.J., Valenzuela D.M., Yancopoulos G.D., Neefjes J.J., Rock K.L. Puromycin-sensitive aminopeptidase limits MHC class I presentation in dendritic cells but does not affect CD8 T cell responses during viral infections. J. Immunol. 2008, 180:1704-1712.
54. Trapp B.D., Nave K.A. Multiple sclerosis: an immune or neurodegenerative disorder?. Annu. Rev. Neurosci. 2008, 31:247-269.
55. Trapp B.D., Peterson J., Ransohoff R.M., Rudick R., Mork S., Bo L. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 1998, 338:278-285.
56. Unterholzner L., Keating S.E., Baran M., Horan K.A., Jensen S.B., Sharma S., Sirois C.M., Jin T., Latz E., Xiao T.S., Fitzgerald K.A., Paludan S.R., Bowie A.G. IFI16 is an innate immune sensor for intracellular DNA. Nat. Immunol. 2010, 11:997-1004.
57. van Baarsen L.G., van der Pouw Kraan T.C., Kragt J.J., Baggen J.M., Rustenburg F., Hooper T., Meilof J.F., Fero M.J., Dijkstra C.D., Polman C.H., Verweij C.L. A subtype of multiple sclerosis defined by an activated immune defense program. Genes Immun 2006, 7:522-531.
58. Venken K., Hellings N., Thewissen M., Somers V., Hensen K., Rummens J.L., Medaer R., Hupperts R., Stinissen P. Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level. Immunology 2008, 123:79-89.
59. Verhagen A.M., Ekert P.G., Pakusch M., Silke J., Connolly L.M., Reid G.E., Moritz R.L., Simpson R.J., Vaux D.L. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000, 102:43-53.
60. Wang X., Chen M., Wandinger K.P., Williams G., Dhib-Jalbut S. IFN-beta-1b inhibits IL-12 production in peripheral blood mononuclear cells in an IL-10-dependent mechanism: relevance to IFN-beta-1b therapeutic effects in multiple sclerosis. J. Immunol. 2000, 165:548-557.
61. Wiendl H., Feger U., Mittelbronn M., Jack C., Schreiner B., Stadelmann C., Antel J., Brueck W., Meyermann R., Bar-Or A., Kieseier B.C., Weller M. Expression of the immune-tolerogenic major histocompatibility molecule HLA-G in multiple sclerosis: implications for CNS immunity. Brain 2005, 128:2689-2704.
62. Wilson S.J., Schoggins J.W., Zang T., Kutluay S.B., Jouvenet N., Alim M.A., Bitzegeio J., Rice C.M., Bieniasz P.D. Inhibition of HIV-1 particle assembly by 2',3'-cyclic-nucleotide 3'-phosphodiesterase. Cell Host Microbe 2012, 12:585-597.
63. Yang Y., Chu W., Geraghty D.E., Hunt J.S. Expression of HLA-G in human mononuclear phagocytes and selective induction by IFN-gamma. J. Immunol. 1996, 156:4224-4231.
64. Zhang X., Markovic-Plese S. Interferon beta inhibits the Th17 cell-mediated autoimmune response in patients with relapsing-remitting multiple sclerosis. Clin. Neurol. Neurosurg. 2010, 112:641-645.
65. Zhang F., Meng G., Strober W. Interactions among the transcription factors Runx1, RORgammat and Foxp3 regulate the differentiation of interleukin 17-producing T cells. Nat. Immunol. 2008, 9:1297-1306.